ECRIN's Director General, Jacques Demotes, is participating in the Economic Forum in Krynica, Poland, from 3 to 5 September 2019. Poland is ECRIN's newest observer country, having joined the organisation on 23 August 2019. Learn more
The PERsonalised MedicIne Trials (‘PERMIT’) project on methodological standards for personalised medicine research has received a positive funding decision from Horizon 2020 (grant agreement number 874825).
ECRIN is pleased to announce that Poland has officially joined as an observer country. The Polish Medical Research Agency will be the national scientific partner.
The Innovative Medicines Initiative (IMI) published its July 2019 newsletter.
ECRIN is recruiting a European Correspondent for Spain, to be based in Barcelona, within ECRIN's Spanish scientific national partner, FCRB. For more information, please click here
ECRIN has published the July 2019 edition of its newsletter.
The EU-CELAC working group on Research Infrastructures was created within the framework of the EU-CELAC Joint Initiative on Research and Innovation, with the purpose of sharing insight on research infrastructures in Europe and Latin American and Caribbean countries.
In Madrid – November 7-8, 2019
The first edition of the EULAC PerMed ‘Summer School’, organised by the EULAC PerMed consortium in collaboration with the Instituto de Salud Carlos III (ISCIII), will be held in Madrid, Spain from November 7 to 8, 2019.
ECRIN is proud to announce that it has now published its 2018 annual report.
ECRIN participated in the EURORDIS Summer School from 10 to 14 June 2019 in Barcelona, Spain.
ECRIN has now launched the 2019 call for its Data Centre Certification programme.
This programme identifies non-commercial clinical trials units (CTUs) in Europe that have demonstrated they can provide safe, secure, compliant and efficient management of clinical research data.
EU-OPENSCREEN-DRIVE is offering funding for chemoproteomics and small molecule screen projects.
5th Call for TRANSVAC2 Training Modules
M10 - Assay Development and Validation-Application of SPR Technologies in Vaccine development and manufacturing
Venue: Fraunhofer IME, Aachen Germany
Dates: 10-11 October 2019
FAIR PARK II (Conservative Iron Chelation as a Disease-Modifying Strategy in Parkinson's Disease), an ECRIN-supported clinical trial, has released its June 2019 newsletter.